# Albireo Pharma Inc. (ALBO)

Source: https://www.quantisnow.com/company/ALBO
Generated: 2026-11-10T21:41:55.916Z

- Ticker: ALBO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2007
- Website: albireopharma.com

## About

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.

## Latest ALBO news and filings

- 2024-02-14 13:33 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-albireo-pharma-inc-amendment-5259701)
- 2023-04-10 15:22 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-albireo-pharma-inc-amendment-4316091)
- 2023-03-14 19:36 UTC [SEC Form 15-12G filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-albireo-pharma-inc-4200032)
- 2023-03-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-albireo-pharma-inc-4177251)
- 2023-03-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-albireo-pharma-inc-4177231)
- 2023-03-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-albireo-pharma-inc-4177220)
- 2023-03-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-albireo-pharma-inc-4177201)
- 2023-03-09 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-albireo-pharma-inc-4177195)
- 2023-03-03 11:05 UTC [SEC Form 4] [SEC Form 4: Chiswell David closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-chiswell-david-closing-all-direct-ownership-in-4157492)
- 2023-03-02 22:02 UTC [SEC Form 4] [SEC Form 4 filed by Alesina Susan](https://www.quantisnow.com/insight/sec-form-4-filed-by-alesina-susan-4155817)
- 2023-03-02 22:01 UTC [SEC Form 4] [SEC Form 4 filed by Okey Stephanie](https://www.quantisnow.com/insight/sec-form-4-filed-by-okey-stephanie-4155804)
- 2023-03-02 22:00 UTC [SEC Form 4] [SEC Form 4: Harford Simon N.R. closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-harford-simon-nr-closing-all-direct-ownership-4155772)
- 2023-03-02 21:58 UTC [SEC Form 4] [SEC Form 4: Cooper Ronald Harold Wilfred closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-cooper-ronald-harold-wilfred-closing-all-direct-4155711)
- 2023-03-02 21:57 UTC [SEC Form 4] [SEC Form 4 filed by Streck Paul](https://www.quantisnow.com/insight/sec-form-4-filed-by-streck-paul-4155682)
- 2023-03-02 21:54 UTC [SEC Form 4] [SEC Form 4: Stephenson Pamela closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-stephenson-pamela-closing-all-direct-ownership-in-4155656)
- 2023-03-02 21:52 UTC [SEC Form 4] [SEC Form 4: Graham Michelle closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-graham-michelle-closing-all-direct-ownership-in-4155606)
- 2023-03-02 21:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155602)
- 2023-03-02 21:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155577)
- 2023-03-02 21:51 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155570)
- 2023-03-02 21:51 UTC [SEC Form 4] [SEC Form 4 filed by Gutch Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-gutch-michael-4155569)
- 2023-03-02 21:50 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155553)
- 2023-03-02 21:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155538)
- 2023-03-02 21:49 UTC [SEC Form POS AM filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-albireo-pharma-inc-4155537)
- 2023-03-02 21:48 UTC [SEC Form 4] [SEC Form 4: Carter Martha J. decreased direct ownership by 50% to 3,654 units](https://www.quantisnow.com/insight/sec-form-4-carter-martha-j-decreased-direct-ownership-by-4155534)
- 2023-03-02 21:49 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155531)
- 2023-03-02 21:47 UTC [SEC Form POS AM filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-albireo-pharma-inc-4155515)
- 2023-03-02 21:47 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155514)
- 2023-03-02 21:46 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155499)
- 2023-03-02 21:46 UTC [SEC Form POS AM filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-albireo-pharma-inc-4155498)
- 2023-03-02 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155484)
- 2023-03-02 21:45 UTC [SEC Form POS AM filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-albireo-pharma-inc-4155478)
- 2023-03-02 21:45 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-albireo-pharma-inc-4155466)
- 2023-03-02 21:44 UTC [SEC Form 4] [SEC Form 4: Duncan Jason closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-duncan-jason-closing-all-direct-ownership-in-4155464)
- 2023-03-02 21:44 UTC [SEC Form POS AM filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-albireo-pharma-inc-4155453)
- 2023-03-02 21:43 UTC [SEC Form 4] [SEC Form 4: Mattsson Jan closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-mattsson-jan-closing-all-direct-ownership-in-4155439)
- 2023-03-02 21:41 UTC [SEC Form 4] [SEC Form 4 filed by Dable Habib J](https://www.quantisnow.com/insight/sec-form-4-filed-by-dable-habib-j-4155426)
- 2023-03-02 21:40 UTC [SEC Form 4] [SEC Form 4 filed by Scoon Davey](https://www.quantisnow.com/insight/sec-form-4-filed-by-scoon-davey-4155399)
- 2023-03-02 21:39 UTC [SEC Form 4] [SEC Form 4 filed by Hopkinson Craig C.](https://www.quantisnow.com/insight/sec-form-4-filed-by-hopkinson-craig-c-4155383)
- 2023-03-02 21:27 UTC [SEC Form 8-K] [Albireo Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/albireo-pharma-inc-filed-sec-form-8-k-completion-of-acquisition-4155038)
- 2023-03-02 21:26 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Albireo Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-albireo-pharma-inc-4154995)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ALBO
- Earnings history: https://www.quantisnow.com/earnings/ALBO
- Dividend history: https://www.quantisnow.com/dividends/ALBO
- Insider transactions: https://www.quantisnow.com/insiders/ALBO
- Options chain: https://www.quantisnow.com/options/ALBO
- SEC 8-K filings only: https://www.quantisnow.com/company/ALBO/8-k
- RSS and alerts for ALBO: https://www.quantisnow.com/docs/rss-feeds.md